Historical Evolution of 3D Bioprinting

The historical development of three-dimensional (3D) bioprinting is deeply intertwined with the evolution of additive manufacturing (AM). Initially conceived as a method to produce plastic and metal prototypes, AM technologies laid the groundwork for constructing living tissues layer by layer. Early pioneers in stereolithography (SLA), fused deposition modeling (FDM), and inkjet-based printing unwittingly paved the path toward bioprinting, which adapts these technical principles to safeguard cell viability and foster biological function. Over the past several decades, groundbreaking milestones in bioink formulations, multi-material and multi-cell printing, and post-printing tissue maturation have ushered 3D bioprinting from speculative possibility to a frontier of tissue engineering and regenerative medicine. This chapter surveys the historical arc of bioprinting, examining how initial ideas of layer-wise fabrication evolved, how researchers and institutions worldwide propelled the field forward, and how challenges related to vascularization, scale-up, and standardization have shaped ongoing practices. We conclude by synthesizing the lessons gleaned from the journey so far, discussing both the crucial breakthroughs that have driven 3D bioprinting closer to clinical implementation and the intricate biological, engineering, and regulatory hurdles that remain. By merging perspectives from additive manufacturing, biomaterials research, and tissue biology, 3D bioprinting continues to inch ever closer to its grand vision of engineered living constructs for therapeutic and research applications.